The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney Disease

• Conditions: Muscle Loss; Polycystic Liver Disease; Polycystic Kidney Diseases
• Interventions: Procedure: Renal artery embolization

• Registration Number: NCT05215964
• Lead Sponsor: National Taiwan University Hospital

Brief Summary

Primary sarcopenia is used to describe aging and progressed with the physiologic decline. Secondary sarcopenia is associated many chronic disease, including acquired immune deficiency syndrome, cancer, chronic heart failure, chronic lung disease, liver cirrhosis, chronic kidney disease and rheumatoid arthritis. In the past, nutrition status is evaluated by body mass index, mid-upper -arm circumference and serum albumin. Bioelectrical impedance analysis is also a common method to measured body composition, but bioelectrical impedance analysis will be affected by tissue edema and ascites. In contrast, cross-section imaging, such as computed tomography and magnetic resonance can analyzed abdominal muscle and fat accurately.

Since computed tomography and magnetic resonance imaging can evaluate the severity of polycystic liver and kidney disease. Investigators can use cross section imaging at 3rd lumber level to separate skeletal muscle and fat tissue. Previous studies showed the quantity and quality of abdominal muscle are important prognostic factor after liver transplantation. Besides, chronic kidney disease and receiving renal placement therapy lead protein catabolism and make patients with end stage renal disease have sarcopenia. Finally, patients with polycystic liver and kidney disease have organomegaly, which causes abdominal distention and poor appetite. Therefore, the aim of this study is to observe the association between skeletal muscle mass and the severity of disease and to study whether change in hepatic and renal volumes is associated with change in muscle mass.

Detailed Description

The imaging study (CT or MRI) will be performed within one month before the procedure to measure total kidney volume and psoas muscle area.

The procedure will use transcatheter embolization to renal artery. The follow-up imaging study will be performed six months after the procedure to measure total kidney volume and psoas muscle area..

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2020-09-29
• Study First Submitted: 2021-05-28
• Status Verified: 2021-10
• Study First Submitted QC: 2022-01-18
• Last Update Submitted: 2022-01-18
• Study First Posted: 2022-01-31
• Last Update Posted: 2022-01-31
• Primary Completion: 2022-12-31
• Study Completion: 2023-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

• Polycystic related disease with medical images (CT or MRI) diagnosed
• Aged over 20 years

Read More

Exclusion Criteria

• Lack of Bio-exam or medical images
• Pregnancy

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
TAE arm	Renal artery embolization	Patients will receive TAE

Primary Outcome Measures

Name	Time	Method
Total psoas muscle change	6 months by imaging study	The change of psoas muscle area before and after procedures.

Secondary Outcome Measures

Name	Time	Method
Total kidney volume change	6 months by imaging study	The change of total kidney volume before and after procedures

Trial Locations

Locations (1)

NTUH; 🇨🇳 Taipei, Taiwan